Fig. 5 -.
Scenario analysis: acceptability curve of the incremental cost-effectiveness ratio of caplacizumab in combination with plasma exchange (PEX) and immunosuppression compared to PEX and immunosuppression.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.